Surveyed U.S. Oncologists Indicate They Would Prescribe Medivation/Astellas Pharma’s Enzalutamide to 30 Percent of Their Second- and Third-Line Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Patients

The mCRPC Drug Market Will Capture $6 Billion by 2020, Corresponding to Two-Thirds of the Total Prostate Cancer Market, According to Findings from Decision Resources

BURLINGTON, Mass.--()--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to positive overall survival data from the Phase III AFFIRM trial and interviewed experts’ enthusiasm for this agent, surveyed U.S. oncologists indicate that they would prescribe Medivation/Astellas Pharma’s enzalutamide (formerly MDV-3100) to 30 percent of their second- and third-line metastatic castrate-resistant prostate cancer (mCRPC) patients.

Decision Resources’ analysis of the prostate cancer drug market also finds that interviewed thought leaders believe that Johnson & Johnson/Janssen Biotech/Janssen-Cilag’s Zytiga will experience a shift in use from the second- and third-line mCRPC setting (its current approved indication) to the first-line, chemotherapy-naive mCRPC setting, assuming that Zytiga successfully obtains a supplemental new drug application (sNDA) for this patient population.

Surveyed U.S. oncologists and managed care organization (MCO) pharmacy directors agree that overall survival is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in second- and third-line mCRPC. Clinical data and the opinions of interviewed thought leaders indicate that enzalutamide, Takeda/Millennium’s orteronel and Algeta/Bayer HealthCare’s Alpharadin have advantages on this attribute over docetaxel (Sanofi’s Taxotere, generics), which was the sales leading agent for the indication in 2010.

According to insights from surveyed U.S. oncologists and MCO pharmacy directors, improving symptom control and quality of life is one of the greatest unmet needs in second- and third-line mCRPC. Clinical data and interviewed thought leaders indicate that enzalutamide, Exelixis’s cabozantinib and Alpharadin have demonstrated the potential to partially fulfill this unmet need.

The prostate cancer drug market will more than double over the next decade, increasing from $3.6 billion in 2010 to more than $9 billion in 2020 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. This market growth will be driven by the launch and uptake of high-priced promising therapies which were unavailable in 2010 and will collectively earn almost $5.5 billion in 2020. In total, the mCRPC drug market (comprising the first-, second-, and third-line settings) will capture $6 billion by 2020, corresponding to two-thirds of the total prostate cancer market.

“Intense clinical development in the mCRPC setting has yielded significant advances and as additional therapies are approved for mCRPC, it will become an increasingly crowded and competitive space,” said Decision Resources Analyst Khurram Nawaz. “Therapies will need to differentiate themselves from one another if they are to maximize clinical and commercial success.”

Decision Resources’ Robust Market Forecast and Opportunities Analysis

Decision Resources provides a comprehensive view of what is happening in a specific drug market now and in the decade ahead. The research includes analysis of the unmet need and near-term drug development opportunities that exist within a drug market powered by primary research from physicians and payers. The robust market forecast and opportunities analysis is comprised of the Pharmacor 2012 advisory service and the DecisionBase 2012 report series.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


Decision Resources
Christopher Comfort, 781-993-2597


Decision Resources
Christopher Comfort, 781-993-2597